Ibandronate Sodium Injection

This product is a bisphosphonate bone resorption inhibitor, which may mainly inhibit the dissolution and formation of hydroxyapatite by binding to the bone, thereby producing an anti-bone resorption effect. Its mechanism of action may also be related to the direct change of the morphology of osteoclasts or the direct inhibition of cytokines mediated by osteoblasts.

1Main ingredients: Ibandronate sodium 2Excipients: Sodium chloride, acetic acid, sodium acetate, water for injection.

This product is a colorless, clear liquid.

This product is suitable for hypercalcemia caused by malignant tumors with or without bone metastasis; it is used to treat bone pain caused by osteolytic bone metastasis of malignant tumors.

This product should be used in hospitals. This product is used for hypercalcemia: 0.9% normal saline should be given for hydration therapy before treatment with this product. The dosage of this product should be determined according to the degree of hypercalcemia and the type of tumor. In most patients with severe hypercalcemia (blood calcium* ≥ 3mmol/L or 12mg/dl after correction with albumin), a single dose of 4mg can be given; in patients with moderate hypercalcemia (blood calcium <3mmol/L or <12mg/dl after correction with albumin), 2mg is the effective dose; the highest dose in foreign clinical studies is 6mg, but this dose did not further increase the efficacy. *Serum calcium corrected by albumin (mmol/L) = serum calcium (mmol/L

A few patients may experience elevated body temperature and sometimes flu-like symptoms, such as fever, chills, and bone and/or muscle aches. In most cases, no specific treatment is needed and symptoms resolve spontaneously after a few hours or days. In some cases, gastrointestinal discomfort may also occur. Due to decreased renal calcium excretion, this is often accompanied by a decrease in serum phosphate levels (usually without treatment). Serum calcium levels may drop below normal.

Patients who are allergic to this product or other bisphosphonates are contraindicated. Children, pregnant women and lactating women are contraindicated. Patients with severe renal insufficiency (serum creatinine> 5mg/dl) are contraindicated.

When this product is used together with aminoglycosides, it may cause a prolonged decrease in blood calcium levels and hypomagnesemia, so extreme caution should be exercised. No studies on the interaction between this product and other drugs have been conducted.

Keep in a dark place and sealed. Valid for 60 months.

1ml:1mg (calculated as ibandronic acid)

Nanjing Hencer Pharmaceutical Co., Ltd.

• Founded in:

  1995-12-27

• Address:

  No. 18, Airport Road, Lishui Economic Development Zone, Nanjing

• Tax NO.:

  9132011713579053XB

• Registered Funds:

  32.142858 million yuan

• Website:

  Log in to view

• Email:

  Log in to view